contact assessment contact assessment and tuberculosis skin testing (tst)
TRANSCRIPT
Contact Assessment
Contact Assessment and Tuberculosis Skin Testing (TST)
Disclosure of Potential for
Conflict of Interest
M. Ruth Deane RN BNCommunicable Disease CoordinatorFINANCIAL DISCLOSUREGrants/Research Support: noneSpeakers Bureau/Honoraria:
noneConsulting Fees: none
Tuberculosis (TB) contact investigations are undertaken to evaluate and follow-up close contacts of active cases, in order to identify secondary cases with active disease, and to identify and treat those with latent tuberculosis infection (LTBI).
Purpose of the TB Investigations
Assessment of a Contact
Symptom review• The following questions
should be asked:- Do you have a cough right now? Has
this cough lasted longer than three weeks?
- Have you coughed up any blood?- Have you lost any weight? Were you
trying to loose weight?- Do you have any fever?
Assessment of a contact con’t
- Do you have night sweats? If yes, is there a known cause? (I.e. menopause, note as a symptom and also note the attributable cause)
- Do you have any pain with breathing?- Are you fatigued?
If any symptom was present, but has since completely resolved, mark as ‘absent’ but with a brief note regarding when they occurred and how long they lasted.
Referral for Sputum
Any contact with a cough lasting three weeks or longer
Should advise those without a cough, but with other symptoms of TB, that we may send for induced sputum based on CXR results
Referral for sputum con’t
Need to provide specimen containers and instructions
Need three samples, at least one should be early morning
Need to be refrigerated until delivered to the laboratory
TB History
Have you ever had TB? • Need documented history of
fully treated disease
Have you ever had a Tuberculin Skin Test?• Need documented result, if
not documented, repeat
High risk conditions when
associated with TB contact
HIV***AIDS***Transplantation (related to
immunosuppressant therapy)SilicosisChronic renal failure requiring
hemodialysis
Hi Risk Conditions Cont
Carcinoma of the head and neckRecent TB infection (< 2 years) Abnormal chest x-ray
fibronodular diseaseTreatment with glucocoriticoids
Increased risk conditions
Tumor necrosis factor alpha (TNF) antagonists• infliximab (Remicade)• etanercept (Enbrel)• adalimumab (Humira)
Increased risk conditions
Diabetes mellitusUnderweight <90% ideal body
weightYoung age when infected(0-4yrs)Cigarette smokerAbnormal chest x-ray -
granuloma
The tuberculin skin test
Different types of tuberculin tests are available
The Mantoux (intradermal) tuberculin skin test is the preferred type because it is the most accurate
The tuberculin used in the skin test is also known a s Purified protein derivative or “PPD”
Storage and handling of Tuberculin
• Date and initial when vial is opened• Discard 30 days after opening• It is sensitive to light, keep out of
light• Draw up just prior to injection• Store at 2 to 8 degrees C° in a
refrigerator or cooler with ice packs
Contraindications
Do not test people who:• Have a documented TST result > 10 mm• Have had TB disease in the past,
confirmed • Have had severe blistering TST reactions
in the past• Have severe eczema• Have a history of anaphylactic reaction to
past TST
Common Side Effects
• Pain• itchiness • discomfort at the test site may
occurTreat with cool cloths or ice. Do
not scratch.
Severe side effects
• Blistering• Ulcers• Necrosis• Scarring from strongly positive
reactions• Anaphylactic reaction
Dosage and Administration
Site: • Left inner aspect of the forearm 2-4
inches below the elbow. • Avoid areas with abrasions, swelling,
visible veins or lesions that will make TST results difficult to interpret.
• Cleanse skin with alcohol swab and allow to dry
Dosage and Administration
Dose:0.1 ml of 5 TU (Tuberculin Units) of
Tuberculin Purified Protein Derivative (Mantoux)
Manufactured by Aventis Pasteur, trade name Tubersol
Supplied by Manitoba TB Control Program for contact testing and select screening programs only
Dosage and Administration
Route: • Intradermally with a 27 gauge, ½
inch needle and 1ml syringe.• Hold skin of the forearm tautly.• Insert needle with bevel up at a 10-
15 degree angle just until the bevel disappears under the skin.
Dosage and Administration
• Slowly inject 0.1 ml Tubersol until activation of safety mechanism
• Look for a discrete, pale elevation of the skin (wheal)
• Wheal should measure 6-10 mm in diameter
• Do not massage the site or cover site with a bandage
Dosage and Administration
If solution leaks from the site or no wheal appears:
• TST will be inaccurate• Repeat injection at least two
inches from the first TST or on the other forearm
Timing of administration
“TST conversion occurs within 8 weeks of exposure and infection. The traditional concept was that conversion occurred in up to 12 weeks. However, all available experimental and epidemiologic evidence consistently shows that this interval is less than 8 weeks.” CTS p 67
How is the skin test read?
Test is read by a trained health worker 48 - 72 hours after the tuberculin injection
Read the TST in good light (may want to bring a pen light) with the forearm supported on a firm surface and the elbow slightly flexed.
Reposition as necessary if interpretation is difficult
How is the skin test read?
Diameter of the indurated (swelling) area is measured across the forearm
Erythema (redness) is not measured
Test result is measured in millimeters (mm)
How is the skin test read?
Find induration by looking at site from the side and then by direct palpation. Mark edges of induration with a pen
Also, using a ballpoint pen, draw a line from the outer edge of the arm inward toward the induration, and stop when the pen comes against the border, repeat from the other side
Only the induration is being measured.
This is CORRECT.
The erythema is being measured. This is INCORRECT.
Routine Practices for TST reading
Wash hands with waterless hand gel or water between clients
Cleanse ruler with alcohol swab between readings
Ensure ‘cover your cough’ policy is enforced
What makes the reaction
significant?
Whether a reaction to the TST is classified as significant, depends on the size of the induration (swelling) and the person’s risk factors for TB
Definition of a significant
(positive)TST
0-4 mm HIV infection with immune suppression and the expected likelihood of TB infection is high (e.g. close contact; abnormal x-ray)
Definition of a significant
(positive)TST
>5 or more millimeters (mm)• Contact to an infectious case of TB• Immunocompromised persons
including HIV infection• Person with an abnormal chest
radiograph, but no evidence of active TB
Definition of a significant
(positive)TST
> 10 or more millimeters (mm)• All other persons
Recording TST results
Record the size of the induration in millimeters
Don’t write ‘negative’ or ‘neg’ but record as 0 mm
Don’t write ‘positive’ or ‘pos’, but record the actual measurement
Factors that can cause a false
positive reading
• Infection with non-tuberculosis mycobacterium
• Vaccination with BCG• Allergic reaction to bandage/tape
used to cover TST • Improper administration of TST• Failure to measure induration
correctly
BCG can be ignored as cause of false
positive if:
• Was given in infancy and the person tested is now 10 years or older
• There is a high probability of TB infection (close contact; high risk community or country of origin)
• There is a high risk of progression from infection to disease
BCG should be considered likely
cause of a positive TST if:
• Was given after 12 months of age AND the person is either Canadian – born non Aboriginal OR an immigrant /visitor from a low TB incidence country.
BCG Scar
Presence of scar indicates that the vaccination ‘took’ or was effective and should be documented.
BCG is administered on the left (usually) shoulder in Manitoba
Other sites include the leg and backSmallpox vaccination last given in 1970 in
Manitoba. No documentation found for other countries
Factors that can cause a false
negative reading• Immune suppression due to:
• Advanced age• Treatment with corticosteroids• Cancer therapy agents• HIV infection• Possible tumor necrosis alfa inhibitors• Malnutrition• Severe illness, including active TB• Major viral illness or immunization within 4 weeks
with MMR, varicella or yellow fever vaccine• Very young age (less than six months)
False negative continued
Technique:• Improper storage• Adsorption• Poor injection technique • Failure to detect/interpret
induration
What is a “boosted” reaction
to a TST
Some persons infected with TB in the past lose their ability to react quickly to TST
A first TB test may be (falsely) negative Another test, one week or more later
(up to one year) will show a (true) positive reaction.
Why do we not do a ‘two-step” in
contact investigations?
In contact investigations, the ‘contact’ (I.e. breathing in the TB bacilli) is the ‘first step’. Therefore only one TST is needed to identify past infection.
Why do we not do a ‘two-step” in
contact investigations?
Two TSTs are done in some investigations based on time since last contact, ie need at least 8 weeks to develop a reaction.
Some of the contacts who are positive on the second test, will be due to a boosted reaction.
Referral for assessment and treatment of LTBI is necessary regardless
So what does a ‘significant’
reaction mean?
We must assume, in the absence of a more definitive test, that a significant reaction indicates tuberculosis infection.
In the absence of a documented <10mm two step baseline with in the last year, we will not know when this infection occurred.
So what does a ‘significant’
reaction mean?
Approximately 5% of immunocompetent newly infected persons will develop primary or progressive primary disease within 18 – 24 months. Those who do not develop primary disease have a 5% chance of reactivation or post primary TB at some time in their lives.
Referral for CXR
• Contacts with significant reactions• Contacts with symptoms consistent
with TB regardless of reaction • Contacts <5 years of age• Immuno-suppressed/HIV contacts
Where, how, who makes the referral?
CXR requisition givenSputum collected as necessaryResults are sent directly to 496 HargraveContacts are referred to either Klinic,
Health Action Centre, Childrens Hospital or Respiratory Outpatients Clinic for assessment and treatment of LBTI
References
Curry International Tuberculosis CenterCanadian Tuberculosis Standards 6th
editionCanadian Immunization Guide 7th
editionManitoba Health Tuberculosis Protocol
December 2009